2738376-89-9
2738376-89-9
Chemical Structure
Avanafil-13C,d3
Synonym(s): TA1790-13C,d3
- CAS No.: 2738376-89-9
- Formula:C2213CH23D3ClN7O3
- Molecular Weight:487.96
IUPAC Name: (S)-4-((3-chloro-4-(methoxy-13C-d3)benzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide
InChIKey: WEAJZXNPAWBCOA-PFMZXWIMSA-N
SMILES: ClC1=C(O[13C]([2H])([2H])[2H])C=CC(CNC2=C(C(NCC3=NC=CC=N3)=O)C=NC(N4[C@H](CO)CCC4)=N2)=C1
Biological Activity: Avanafil-13C,d3 is the 13C- and deuterium labeled Avanafil.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Avanafil-13C,d3 | Avanafil-13C,d3 is the 13C- and deuterium labeled Avanafil. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Avanafil (Standard) | ≥98% | Avanafil (Standard) is the analytical standard of Avanafil. This product is intended for research and analytical applications. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Avanafil-13C5 | Avanafil-13C5 (TA1790-13C5) is 13C labeled Avanafil. Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Avanafil-13C5,15N,d2 | Avanafil-13C5,15N,d2 is 15N and deuterated labeled Avanafil (HY-18252). Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Avanafil-d4 | Avanafil-d4 (TA1790-d4) is deuterium-labeled Avanafil (HY-18252). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Avanafil | 98.00% | Avanafil (TA-1790) is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor with IC50 values of 5.2 nM, 630 nM, 5700 nM, 6200 nM, 12000 nM, 27000 nM, 51000 nM and 53000 nM for PDE-5, PDE-6, PDE-4, PDE-10, PDE-8, PDE-7, PDE-2 and PDE-1, respectively. Avanafil activates NO/cGMP/PKG signaling-pathway to decrease loss in BMD, bone atrophy, and oxidative stress. Avanafil inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels. Avanafil can be used for the research of erectile dysfunction and osteoporosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
